Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 ...

Wave Life Sciences announced the submission of its first clinical trial application for WVE-007, an investigational siRNA designed to silence INHBE gene expression, inducing fat burning for sustainable weight loss without impacting muscle mass. Wave expects CTA approval and initiation of the first-in-human study in 1Q 2025.